Since early May, and as of 11 October 2022, 20 455 confirmed cases of monkeypox (MPX) have been reported from 29 European Union/European Economic Area (EU/EEA) countries, including four deaths. As of 30 September, MPX confirmed cases reported from EU/EEA countries represented almost one third (29.7%) of the cases reported to the World Health Organization (WHO) globally (68 267 cases).
Since early May 2022 and as of 7 July, cases of monkeypox (MPX) have been reported in non-endemic countries. Twenty-six European Union/European Economic Area (EU/EEA) countries have reported 4 908 cases, representing 65% of all cases reported worldwide in 2022.
Cases of monkeypox (MPX) acquired in the EU have recently been reported in nine EU Member States (Austria, Belgium, France, Germany, Italy, Portugal, Spain, Sweden, and the Netherlands).
The risks assessed in this document are of the introduction and further spread of monkeypox in the EU/EEA, infection with regards to different settings (e.g. healthcare, community, etc.) and transmission through SoHO.
As of 30 August 2018, Algeria has reported 74 confirmed cholera cases from six northern and coastal areas of the country. This is the first cholera outbreak reported in Algeria in more than 20 years.
This rapid risk assessment addresses the public health risk associated with the early occurrence of a large number of West Nile virus infections in the EU/EEA and EU neighbouring countries in 2018.
ECDC observed a significant increase in the number of cases of travel-associated Legionnaires’ disease (TALD) in EU travellers returning from Dubai during the period October 2016 to May 2017 that could not be accounted for by the increase in travel patterns from the EU.
The production of this rapid risk assessment was triggered by a report by the Czech Republic of two travelassociated cases of cholera from Zanzibar (Tanzania) and the cholera epidemics in the Horn of Africa and the Gulf of Aden.